JCR Pharma announced its financial results for the fiscal year ending June 2026, reporting a capital partnership with its parent company Medipal Holdings and agreements related to the overseas commercialization of new drug candidates.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4552-20260623-01.pdf","jir_short_summary":"JCR Pharma announced its financial results for the fiscal year ending June 2026, reporting a capital partnership with its parent company Medipal Holdings and agreements related to the overseas commercialization of new drug candidates.","jir_summary":"### Performance Overview\nJCR Pharma announced its financial results for the fiscal year ending June 2026, continuing its capital partnership with its parent company Medipal Holdings. Medipal is the largest shareholder with a voting rights ratio of 23.86%, and both companies are advancing business initiatives that leverage their respective strengths. The report also includes progress on agreements for the overseas commercialization of its new drug candidates and developments in treatments for rare diseases.\n\n### Future Outlook and Impact on Shareholders\nThe company will continue to integrate drug discovery and sales capabilities to expand its business. Through collaboration with Medipal, it aims to promote overseas expansion of treatments for rare diseases and the commercialization of new drug candidates, striving to enhance long-term corporate value. For shareholders, strengthened partnerships and advancements in new drug development are expected to be key drivers of growth.","jir_financial_highlights":"Voting Rights Ownership Percentage (%): 23.86 (Unknown)","jir_category":"","jir_hashtags":"#JCRPharma, #FinancialResults, #JapaneseStocks","jir_key_figures":"Voting Rights Ownership Percentage (%): 23.86\nInterim profit attributable to parent company shareholders: Unknown\nAgreement for overseas commercialization of new drug candidates: Unknown","jir_meta_title":"\u3010JCR Pharma\u3011Fiscal Year Ending June 2026 Financial Results and New Drug Partnership\uff5cJune 2026","jir_meta_description":"JCR Pharma announced its financial results for the fiscal year ending June 2026, reporting a capital partnership with Medipal and overseas development of new drug candidates. Future outlook and impact on shareholders are also discussed.","jir_og_title":"\u3010JCR Pharma\u3011Fiscal Year Ending June 2026 Financial Results and Partnership Details\uff5cJune 2026","jir_og_description":"JCR Pharma announced its fiscal year ending June 2026 financial results and new drug partnerships. Strategies for long-term growth and shareholder expectations are outlined.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-67739","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n